In a patient with atrial fibrillation and moderate mitral valve stenosis, what is the most appropriate treatment for ventricular rate control?

In a patient with atrial fibrillation and moderate mitral valve stenosis, what is the most appropriate treatment for ventricular rate control?

• A. Immediate direct current cardioversion.
• B. Amiodarone 300 mg intravenously over 1 hour.
• C. Digoxin 0.25 mg intravenously.
• D. Diltiazem 0.25 mg/kg intravenously over 2 minutes.

Answer: (D)

In patients with atrial fibrillation and moderate mitral valve stenosis, ventricular rate control is crucial to prevent rapid ventricular rates that can lead to symptoms of heart failure or other complications. Diltiazem, a calcium channel blocker, is a suitable choice for rate control in this scenario because it effectively slows down the conduction through the AV node, reducing the ventricular response rate to atrial fibrillation. The intravenous formulation allows for rapid onset of action, which is beneficial in acute settings. Diltiazem, by limiting calcium influx, also helps to lower myocardial oxygen demand and can improve symptoms in patients with concomitant heart failure or other ischemic concerns. Given that mitral valve stenosis can lead to increased pressure in the left atrium, resulting in atrial dilation and possible thrombus formation, controlling the ventricular rate is fundamental to managing the patient's condition effectively. In this scenario, it is important to prioritize options that specifically target ventricular rate control without exacerbating the underlying stenosis or causing other complications. Other treatments, such as digoxin, while helpful in certain contexts, primarily have a slower onset of action and may not be the first choice for immediate rate control in an acute situation. Meanwhile, options like cardioversion and amiodarone

In patients with atrial fibrillation and moderate mitral valve stenosis, ventricular rate control is crucial to prevent rapid ventricular rates that can lead to symptoms of heart failure or other complications. Diltiazem, a calcium channel blocker, is a suitable choice for rate control in this scenario because it effectively slows down the conduction through the AV node, reducing the ventricular response rate to atrial fibrillation. The intravenous formulation allows for rapid onset of action, which is beneficial in acute settings.

Diltiazem, by limiting calcium influx, also helps to lower myocardial oxygen demand and can improve symptoms in patients with concomitant heart failure or other ischemic concerns. Given that mitral valve stenosis can lead to increased pressure in the left atrium, resulting in atrial dilation and possible thrombus formation, controlling the ventricular rate is fundamental to managing the patient's condition effectively.

In this scenario, it is important to prioritize options that specifically target ventricular rate control without exacerbating the underlying stenosis or causing other complications. Other treatments, such as digoxin, while helpful in certain contexts, primarily have a slower onset of action and may not be the first choice for immediate rate control in an acute situation. Meanwhile, options like cardioversion and amiodarone